In this issue:
Intensive glucose control in T2DM
Dapagliflozin and kidney disease progression in T2DM
Oral semaglutide in T2DM with moderate renal impairment
Flexible-dose oral semaglutide vs. sitagliptin in T2DM
Insulin degludec + liraglutide vs. insulin glargine in T2DM
Adjunctive liraglutide in persistent/ recurrent T2DM after metabolic surgery
Baseline HbA1c and efficacy of current glucose-lowering therapies
T2DM in midlife and cerebrovascular disease risk in later life
Combination gut peptides in obese patients with prediabetes or T2DM
Eplerenone: effects on liver fat and metabolism in T2DM
Please login below to download this issue (PDF)